Psoriasis and Metabolic Syndrome

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Lipid Metabolism".

Deadline for manuscript submissions: 15 July 2025 | Viewed by 480

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland
Interests: psoriasis; psoriatic arthritis; metabolic diseases; genetic and epigenetic factors; markers; therapy; immunology; pathogenesis; lipids
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic autoimmune and inflammatory disease affecting 2–4% of the population. To date, psoriasis has been regarded as a systemic disease closely related to numerous cardiometabolic disorders, especially metabolic syndrome (MS), which affects 20–60% of psoriatic. People with psoriasis have a shortened life expectancy, mainly due to cardiovascular diseases and increased relative risk of mortality in comparison to the general population, which correlates with the severity of the disease. The multidirectional relationship of psoriasis with various comorbidities is translated by common genetic or immunological inflammation, but especially with systemic metabolically driven inflammation, which is crucial in psoriasis pathogenesis and leads to the development of atherosclerosis, insulin resistance, and further cardiometabolic complications. There have been continuous research efforts searching for novel markers and metabolites to evaluate or screen for cardiometabolic risk in order to enable early detection, followed by more effective and newer therapeutic interventions.

This Special Issue, “Psoriasis and Metabolic Syndrome”, will present the current knowledge on psoriasis and its metabolic comorbidities, with a special emphasis on the newest contexts of the pathogenesis, treatment and validation of innovative potential markers to give readers a deeper understanding of these complex interrelations.

Prof. Anna Baran
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • metabolic diseases
  • genetic and epigenetic factors
  • markers
  • therapy
  • immunology
  • pathogenesis
  • lipids

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2048 KiB  
Article
Apolipoproteins in Psoriasis: The Effect of Acitretin Treatment and UVB Phototherapy
by Hanna Myśliwiec, Dorota Kozłowska, Katarzyna Hodun, Bartłomiej Łukaszuk, Agnieszka Owczarczyk-Saczonek, Adrian Chabowski and Iwona Flisiak
Metabolites 2025, 15(3), 196; https://doi.org/10.3390/metabo15030196 - 12 Mar 2025
Viewed by 238
Abstract
Background: Psoriasis is a chronic, multi-system inflammatory disease frequently associated with metabolic syndrome and lipid disturbances. Apolipoproteins, as essential regulators of lipid metabolism, may play a critical role in these metabolic abnormalities, potentially influencing disease severity and systemic inflammation. The aim of this [...] Read more.
Background: Psoriasis is a chronic, multi-system inflammatory disease frequently associated with metabolic syndrome and lipid disturbances. Apolipoproteins, as essential regulators of lipid metabolism, may play a critical role in these metabolic abnormalities, potentially influencing disease severity and systemic inflammation. The aim of this study was to compare serum concentrations of chosen apolipoproteins in patients with psoriasis before and after treatment with acitretin or narrowband UVB (NB-UVB). Methods: This study was conducted on 39 patients with psoriasis. The concentration of nine apolipoproteins and C-reactive protein was quantified using the Bio-Plex Immunoassay Kit. Results: The serum concentrations of ApoA2, ApoC1, ApoD, ApoE, and ApoJ were higher in the acitretin group compared to the NB-UVB group before treatment, while the ApoA1/ApoA2 ratio was lower. We also observed a negative association between the Psoriasis Area and Severity Index (PASI) and ApoA1/ApoA2 ratio in the patients before the treatment. Conclusions: The results of this study confirm the presence of metabolic disturbances in psoriatic patients. The treatment with NB-UVB or acitretin did not cause any significant changes in the apolipoproteins profile. Thus, we found no detrimental impact of acitretin on the apolipoproteins profile, despite the observed rise in total cholesterol concentration after the treatment. Further research is needed to explore whether specific therapeutic approaches can modify these disturbances and potentially improve long-term cardiovascular outcomes in this population. Full article
(This article belongs to the Special Issue Psoriasis and Metabolic Syndrome)
Show Figures

Figure 1

Back to TopTop